Rafael Holdings Q3 net loss narrows to $4.8M; Phase 3 data expected this month

Rafael Holdings, Inc.

2025-Q3 EPS reported -$0.73 revenue$567,000

Net loss attributable to Rafael Holdings of $4.8M ($0.19 per share) vs. $32.4M loss ($1.36) in Q3 last year.
Cash and equivalents of $37.9M at April 30, 2025; $25M rights offering closed June 4 with net proceeds of $24.9M.
Cyclo Therapeutics merger completed March 25, 2025; TransportNPC Phase 3 trial fully enrolled for NPC1.
48-week interim analysis results for Trappsol Cyclo expected later this month.
R&D expenses rose to $3.0M and G&A to $3.2M due to Cyclo consolidation.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.